SpyGlass Pharma, Inc. (SGP)
| Market Cap | 922.56M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 33.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,340 |
| Open | 28.00 |
| Previous Close | 28.22 |
| Day's Range | 27.69 - 28.85 |
| 52-Week Range | 20.16 - 32.44 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SGP
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, In... [Read more]
News
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial publi...
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
SpyGlass Pharma Announces Pricing of Initial Public Offering
ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial publi...
SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates
SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. SGP's BIM-IOL System demonstrated a 37% mean intraocular pressure reduction at 36 ...
SpyGlass Pharma, Sustained-Release Ophthalmic Drug-Delivery Company, Files for Nasdaq Global Select Market IPO
SpyGlass Pharma filed for an initial public offering on the Nasdaq Global Select Market under the ticker SGP. The late-stage biopharmaceutical company is developing sustained-release drug-delivery sys...
SpyGlass Pharma IPO Registration Document (S-1)
SpyGlass Pharma has filed to go public with an IPO on the NASDAQ
Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.